FOLFIRI方案二线治疗晚期十二指肠癌的临床观察

Clinical observation of FOLFIRI as second-line chemotherapy for advanced duodenal cancer

目的探讨FOLFIRI方案二线治疗晚期十二指肠癌的疗效和安全性。方法回顾分析本院2008年6月至2016年1月接受FOLFIRI方案二线治疗的晚期十二指肠癌患者9例,分别采用RECIST 1.1版与NCI-CTC 4.0版标准评价近期疗效和不良反应。采用Kaplan-Meier法进行生存分析。结果 9例患者均可评价疗效和不良反应,共完成化疗41个周期,中位化疗4个周期(3~8个周期)。9例患者获PR 1例,SD 5例和PD 3例,总有效率和疾病控制率分别为11.1%和66.7%,中位无进展生存期为6.5个月,中位生存期为19.3个月。常见不良反应多为1~2级,主要为白细胞减少、中性粒细胞减少、贫血、乏力、恶心等。结论 FOLFIRI方案对一线治疗失败后的晚期十二指肠癌具有较好的疗效,且耐受性较好。

Objective To evaluate the efficacy and safety of FOLFIRI as second-line chemotherapy for advanced duodenal cancer.Methods Patients with advanced duodenal cancer who have failed to first-line therapy from June 2008 to January 2016 were analyzed retrospectively.Nine patients received FOLFIRI regiments as second-line chemotherapy.The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria.Overall survival （OS） and progression-free survival （PFS） were analyzed by Kaplan-Meier method.Results All patients were available for evaluating toxicity and effectiveness.The total treatment cycle was 41, and the median treatment cycle was 4（3-8 cycles）.The response rate was 11.1% and disease control rate was 66.7%, including 1 case of PR, 5 cases of SD and 3 cases of PD.The median OS was 19.3 months and the median PFS was 6.5 months.The major treatment-related side effects including leucopenia, neutropenia, anemia, fatigue, nausea and etc, were mainly in grade 1-grade 2.Conclusion FOLFIRI is effective and tolerable in advanced duodenal cancer as second-line chemotherapy.